Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026)

Nuvectis Pharma has reported Accumulated Expenses for 6 years, with the latest figure at $36000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 99.29% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36000.0 (down 99.29% YoY) and the FY2025 annual result came in at $115000.0, down 97.93% from the prior year.
• Accumulated Expenses declined to $36000.0 in Q1 2026 per NVCT's latest filing, from $115000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.6 million in Q4 2024 and troughed at $2000.0 in Q2 2025.
• A 5-year average of $1.9 million and a median of $863000.0 in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 2287.97% in 2024, then tumbled 99.94% in 2025.
• Over 5 years, Accumulated Expenses stood at $445000.0 in 2022, then jumped by 753.48% to $3.8 million in 2023, then surged by 46.29% to $5.6 million in 2024, then plunged by 97.93% to $115000.0 in 2025, then sank by 68.7% to $36000.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $36000.0, $115000.0, and $65000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.